| Literature DB >> 26688341 |
Ersilia Nigro1, Irene Colavita1, Daniela Sarnataro1,2, Olga Scudiero1,2, Gerardo Zambrano1, Vincenzo Granata1, Aurora Daniele1,3, Alfonso Carotenuto4, Stefania Galdiero4,5, Veronica Folliero6, Massimiliano Galdiero6, Richard A Urbanowicz7, Jonathan K Ball7, Francesco Salvatore1,8, Antonello Pessi1.
Abstract
Host defence peptides (HDPs) are critical components of innate immunity. Despite their diversity, they share common features including a structural signature, designated "γ-core motif". We reasoned that for each HDPs evolved from an ancestral γ-core, the latter should be the evolutionary starting point of the molecule, i.e. it should represent a structural scaffold for the modular construction of the full-length molecule, and possess biological properties. We explored the γ-core of human β-defensin 3 (HBD3) and found that it: (a) is the folding nucleus of HBD3; (b) folds rapidly and is stable in human serum; (c) displays antibacterial activity; (d) binds to CD98, which mediates HBD3 internalization in eukaryotic cells; (e) exerts antiviral activity against human immunodeficiency virus and herpes simplex virus; and (f) is not toxic to human cells. These results demonstrate that the γ-core within HBD3 is the ancestral core of the full-length molecule and is a viable HDP per se, since it is endowed with the most important biological features of HBD3. Notably, the small, stable scaffold of the HBD3 γ-core can be exploited to design disease-specific antimicrobial agents.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26688341 PMCID: PMC4685272 DOI: 10.1038/srep18450
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Modular structure of HBD3 and γ-core peptides.
(A) Sequences of the peptides used in this study. In the peptides, Cys23, Cys 33 and Cys40 (HBD3 numbering) are mutated to Ser. (B) peptide β: theγ-core motif of HBD3 as identified bioinformatically by Yount & Yeoman (Yount and Yeaman, 2004); peptide γ: theβ-hairpin enclosed by the disulfide Cys23-Cys41 which encompasses the γ-core; peptide φ: theCys23-Cys41 β-harpin containing the γ-core motif (blue) linked to the third strand of the β-sheet (cyan) by the Cys18-Cys33 disulfide; peptide α: the β-sheet containing the γ-core motif is linked to the α-helical domain (green) through the Cys11-Cys40 disulfide to complete the full-length peptide. The figure was built with Pymol using for HBD3 the PDB code 1KJ6 (Schibli, et al., 2002). (C) Time-course of the oxidative folding of 0.5 mg/mL HBD3 in Tris HCl, pH 7.5. Aliquots of the folding mixture at various time points were treated with iodoacetamide, and excess reagent removed by HPLC. Following trypsin treatment, fragments were identified by MS. Shown is the structure of the fragments found at the indicated times, which define the sequence of disulfide bond formation during refolding. See also Figures S1, S2, Tables S1–S4.
Figure 2The γ-core peptides have potent antimicrobial activity without affecting cell viability.
Antibacterial activity of peptides γ,δ,ε in comparison with full-length HBD3 on (A) E. coli. and (B) P. aeruginosa, and (C) S. aureus at the concentration of 2.5 μM (blue bars) and 12.5 μM (red bars), in the presence of the indicated concentrations of NaCl. Error bars show the standard deviations (SDs) from three independent experiments. Based on the absence of activity on E. coli, peptide δ was not tested on the other species. (D) Effects of the indicated peptides tested at the indicated concentration on A549 cells viability by MTT test. The data are expressed as the means ± standard error of three independent experiments. (E) Effects of the γ-core peptides on HIV infectivity. The γ-core peptides γ and ε were tested in oxidized and reduced form on the indicated HIV-1 viral strains at the concentration of 1, 5, 10, 20, 50, 100 and 150 μM, in comparison with reduced HBD3. Data expressed as % neutralization are from triplicates, with indicated SD. The same data in Table format are in the S.I. See also Tables S6, S7.
Kinetic and equilibrium constants for the interaction of CD98 with HBD3 and the γ-core peptides γ and ε.
| Immobilized | In solution | |||||
|---|---|---|---|---|---|---|
| CD98103-630 | HBD3 | 8.51 ± 0.05 | 2.10 ± 0.03 | 9.03 ± 0.06 | 1.930 ± 0.03 | 4.35 ± 0.06 |
| CD98103-630 | Peptide γ | 3.91 ± 0.01 | 3.57 ± 0.07 | 8.29 ± 0.07 | 0.540 ± 0.06 | 0.55 ± 0.07 |
| CD98103-630 | Peptide ε | 0.73 ± 0.02 | 5.48 ± 0.03 | 1.24 ± 0.04 | 0.128 ± 0.04 | 0.06 ± 0.04 |
| CD98304-414 | HBD3 | 4.65 ± 0.07 | 1.26 ± 0.03 | 5.44 ± 0.06 | 0.907 ± 0.007 | 3.86 ± 0.07 |
| CD98304-414 | Peptide γ | 3.95 ± 0.04 | 3.44 ± 0.06 | 7.55 ± 0.06 | 0.152 ± 0.05 | 0.52 ± 0.06 |
| CD98304-414 | Peptide ε | 0.71 ± 0.04 | 5.38 ± 0.05 | 5.67 ± 0.05 | 0.116 ± 0.06 | 0.06 ± 0.06 |
Reduction in HSV Infectivity (% of control) upon treatment with γ-core peptides γ and ε or HBD3 at the indicated concentrations and conditions.
| Peptide | Concentration (μM) | Condition | ||||||
|---|---|---|---|---|---|---|---|---|
| 1 | 5 | 10 | 20 | 50 | 100 | 150 | ||
| HBD3 | 15 | 20 | 36 | 55 | 67 | 79 | 94 | Virus pre-treatment |
| HBD3 | 32 | 45 | 64 | 82 | 95 | 100 | 100 | Cell pre-treatment |
| HBD3 | 18 | 30 | 50 | 80 | 97 | 100 | 100 | Co-treatment |
| HBD3 | 0 | 0 | 0 | 0 | 5 | 7 | 12 | Post-treatment |
| Peptide γ ox | 0 | 6 | 15 | 20 | 28 | 38 | 47 | Virus pre-treatment |
| Peptide γ red | 0 | 0 | 8 | 18 | 20 | 31 | 36 | Virus pre-treatment |
| Peptide γ ox | 0 | 15 | 26 | 30 | 38 | 54 | 65 | Cell pre-treatment |
| Peptide γ red | 0 | 12 | 12 | 18 | 32 | 51 | 53 | Cell pre-treatment |
| Peptide γ ox | 15 | 20 | 23 | 31 | 46 | 53 | 68 | Co-treatment |
| Peptide γ red | 7 | 12 | 20 | 28 | 38 | 46 | 59 | Co-treatment |
| Peptide γ ox | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Post-treatment |
| Peptide γ red | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Post-treatment |
| Peptide ε ox | 0 | 0 | 7 | 12 | 19 | 28 | 33 | Virus pre-treatment |
| Peptide ε red | 0 | 0 | 3 | 8 | 16 | 26 | 31 | Virus pre-treatment |
| Peptide ε ox | 0 | 0 | 15 | 18 | 23 | 32 | 41 | Cell pre-treatment |
| Peptide ε red | 0 | 10 | 10 | 12 | 17 | 28 | 42 | Cell pre-treatment |
| Peptide ε ox | 12 | 18 | 21 | 36 | 38 | 42 | 57 | Co-treatment |
| Peptide ε red | 3 | 13 | 18 | 22 | 33 | 38 | 48 | Co-treatment |
| Peptide ε ox | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Post-treatment |
| Peptide ε red | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Post-treatment |
Figure 3Hypothetical evolutionary pathway of HBD3.
The structures along the pathway are shown, together with a schematic list of associated structural and biological features taken from the literature or established in the present work. For an extended description see text.